Posted by Michael Wonder on 08 Feb 2022
NICE misses golden opportunity to enhance access to innovative cancer drugs
7 February 2022 - Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs.
The Institute of Cancer Research, London, said NICE's proposed reforms to its methods for assessing drugs for the NHS fell short of what was needed and in one important respect could make access to new cancer drugs worse.
